TIMP-3 gene therapy
Latest Information Update: 23 Apr 2002
At a glance
- Originator Nonindustrial source
- Class Anti-ischaemics; Gene therapies
- Mechanism of Action Metalloprotease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Ischaemic heart disorders
Most Recent Events
- 23 Jul 1999 New profile
- 23 Jul 1999 Preclinical development for Ischaemic heart disorders in United Kingdom (Unknown route)